Russia under threat of shortage of anti-HIV drugs

22 November 2022

Representatives of the Russian patient community have warned about the shortage of the antiretroviral drug Eviplera (rilpivirine/tenofovir/emtricitabine), the most popular and most expensive combination drug for the treatment of HIV on the domestic market, reports The Pharma Letter’s local correspondent.

While some of local doctors and analysts explain the interruptions in supplies by anti-Russian sanctions, other sure that the problem is related with too high price of the drug of more than 300,000 roubles ($4,950) for the annual treatment course.

So far, Patient Control (a public organization which unites people living with HIV in Russia) has reported on the shortage of the ARV drug Eviplera, marketed by the America’s Johnson & Johnson (NYSE: JNJ) and Gilead Sciences (Nasdaq: GILD), with the most complex situation being observed in the Russian province.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK